22:27 , Feb 2, 2018 |  BioCentury  |  Finance

Building momentum

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates. Cormorant Asset Management and...
13:13 , Feb 1, 2018 |  BC Extra  |  Financial News

Cell therapy play Avrobio raises $60M

Avrobio Inc. (Cambridge, Mass.) raised $60 million in a series B round co-led by Cormorant Asset Management and Surveyor Capital. Fellow new investors Aisling, Brace Pharma Capital, Eventide, Morningside and Leerink Partners also participated alongside...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017...
21:41 , Dec 1, 2017 |  BC Week In Review  |  Company News

Avrobio acquires cystinosis program from GenStem

In October, GenStem Therapeutics Inc. (San Diego, Calif.) granted Avrobio Inc. (Cambridge, Mass.) exclusive, worldwide rights to cystinosis gene therapy AVR-RD-04. Financial details are not disclosed. GenStem, a University of California San Diego spinout, will...